Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

about

Review article: dose optimisation of infliximab for acute severe ulcerative colitis.

P2860

Q30239077-993425EF-11DC-4EAE-9100-ED404B196A61

P2860

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

Item

http://www.wikidata.org/entity/Q58694439

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2011

@uk

name

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@en

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@nl

type

Item

label

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@en

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@nl

prefLabel

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@en

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@nl

P1476

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

@en

P2093

E. J. Paulssen

http://www.w3.org/2001/XMLSchema#string

G. Cui

http://www.w3.org/2001/XMLSchema#string

G. Øverland

http://www.w3.org/2001/XMLSchema#string

I. Christiansen

http://www.w3.org/2001/XMLSchema#string

J. Florholmen

http://www.w3.org/2001/XMLSchema#string

R. Goll

http://www.w3.org/2001/XMLSchema#string

R. Rismo

http://www.w3.org/2001/XMLSchema#string

T. Olsen

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

Infliximab for induction and maintenance therapy for ulcerative colitis

The immunological and genetic basis of inflammatory bowel disease.

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.

New insights into the pathogenesis of inflammatory bowel disease.

Systematic review: Infliximab therapy in ulcerative colitis.

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis.

Therapeutic strategies for the management of ulcerative colitis.

Immunosuppression in inflammatory bowel disease: traditional, biological or both?

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/156407

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

about

P2860

P2860

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577